1251529-10-8

Basic information

• Product Name: C₁₉H₂₅ClN₂O₃
• Synonyms: C₁₉H₂₅ClN₂O₃
• CAS NO: 1251529-10-8
• Molecular Weight: 364.872
• Mol File: 1251529-10-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₁₉H₂₅ClN₂O₃(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₉H₂₅ClN₂O₃(1251529-10-8)
• EPA Substance Registry System: C₁₉H₂₅ClN₂O₃(1251529-10-8)

Safety Data

• Hazardous Substances Data: 1251529-10-8(Hazardous Substances Data)

Upstream product

• 16422-27-8 1,5-dimethyl (2R)-2-aminopentanedioate 
• 1251529-07-3 1-(4-chloro-3-methyl-benzyl)-piperidin-4-one 
• 92304-76-2 1-chloro-4-(chloromethyl)-2-methylbenzene 
• 1251529-08-4 C₂₃H₃₅ClN₂O₄ 
• 117890-58-1 4-(bromomethyl)-1-chloro-2-methylbenzene 
• 13515-99-6 D-glutamic acid dimethyl ester hydrochloride 
• 1251529-09-5 C₁₉H₂₇ClN₂O₄ 

Downstream Products

• 1251529-11-9 1-[1-(4-chloro-3-methyl-benzyl)-piperidin-4-yl]-5-oxo-pyrrolidine-2-carboxylic acid 
• 1251527-64-6 C₂₆H₃₁ClN₄O₄ 
• 1251527-67-9 C₂₆H₃₁ClN₄O₄ 

Relevant articles and documents

PROCESS FOR THE MANUFACTURING OF CRR INHIBITORS

The present invention relates to a process for preparing CCR3 inhibitors of formula 1, wherein R1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl; R2 is H, C1-6-alky

SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS

Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.